Abstract: The invention relates to aqueous skin cleansing compositions. Specific amounts and chain length of acyl glycinate and acyl glutamate when used in specified ratios, have been found to unexpectedly enhance lather volume and texture, as well as provide superior mildness.

Abstract: The invention relates to aqueous skin cleansing compositions. Specific amounts and chain length of acyl glycinate and acyl glutamate when used in specified ratios, have been found to unexpectedly enhance lather volume and texture, as well as provide superior mildness.

Abstract: Disclosed is a skin care composition comprising 0.0001 to 10% of phospholipid by weight of the composition, porous particle and silicone elastomer.

Abstract: The invention relates to aqueous skin cleansing compositions. Specific amounts and chain length of acyl glycinate and acyl glutamate when used in specified ratios, have been found to unexpectedly enhance lather volume and texture, as well as provide superior mildness.

Abstract: The invention relates to aqueous skin cleansing compositions. Specific amounts and chain length of acyl glycinate and acyl glutamate when used in specified ratios, have been found to unexpectedly enhance lather volume and texture, as well as provide superior mildness.

Abstract: The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase A2 (PLA2), and COX-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions. The compounds and plant extracts can also be used to produce comestible compositions to be incorporated into a normal diet to improve health or prevent or reduce the uptake of free fatty acids during digestion or the production of inflammatory eicosanoids or cytokines. The inhibitor compounds and compositions include cocoa-derived polymers of epicatechin, such as epicatechin-rich polymers of 2 units through polymers of 14 units, or 5 to 14 units, and combinations of them.

Abstract: The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase A2 (PLA2), and COX-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions. The compounds and plant extracts can also be used to produce comestible compositions to be incorporated into a normal diet to improve health or prevent or reduce the uptake of free fatty acids during digestion or the production of inflammatory eicosanoids or cytokines. The inhibitor compounds and compositions include cocoa-derived polymers of epicatechin, such as epicatechin-rich polymers of 2 units through polymers of 14 units and combinations of them.